Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the thermodynamic, kinetic and inhibitory mechanisms of 5-iTU targeting mitotic kinase haspin by integrated molecular dynamics.

Physical chemistry chemical physics : PCCP·2021
Same author

IS<i>1294</i> Reorganizes Plasmids in a Multidrug-Resistant Escherichia coli Strain.

Microbiology spectrum·2021
Same author

Enhanced Fog Harvesting through Capillary-Assisted Rapid Transport of Droplet Confined in the Given Microchannel.

ACS applied materials & interfaces·2021
Same author

TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway.

Journal of cellular and molecular medicine·2021
Same author

Rescuing eGFP-Tagged Canine Distemper Virus for 40 Serial Passages Separately in Ribavirin- and Non-Treated Cells: Comparative Analysis of Viral Mutation Profiles.

Frontiers in cellular and infection microbiology·2021
Same author

Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases.

Oxidative medicine and cellular longevity·2021

Related Experiment Video

Updated: Jun 6, 2026

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
07:22

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

Published on: January 12, 2024

Research progress and future perspectives in proteolysis-targeting chimeras.

Nuofan Wu1,2, Zihui Xu1, Shuhong Dai1

  • 1School of Food and Drug, Shenzhen Polytechnic University, Shenzhen, China.

Frontiers in Pharmacology
|June 5, 2026
PubMed
Summary
This summary is machine-generated.

Proteolysis-targeting chimeras (PROTACs) offer a novel way to degrade disease-causing proteins by using the body's natural systems. This review explores PROTACs' potential, challenges, and future directions in medicine.

Keywords:
E3 ubiquitin ligaseclinical translationpharmacokineticsproteolysis-targeting chimera (PROTAC)targeted protein degradation (TPD)ubiquitin-proteasome system

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Identification of Functional Protein Regions Through Chimeric Protein Construction
11:39

Identification of Functional Protein Regions Through Chimeric Protein Construction

Published on: January 8, 2019

Related Experiment Videos

Last Updated: Jun 6, 2026

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
07:22

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

Published on: January 12, 2024

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Identification of Functional Protein Regions Through Chimeric Protein Construction
11:39

Identification of Functional Protein Regions Through Chimeric Protein Construction

Published on: January 8, 2019

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Proteolysis-targeting chimeras (PROTACs) are a new therapeutic modality that uses targeted protein degradation (TPD) to remove disease-causing proteins.
  • PROTACs leverage the ubiquitin-proteasome system (UPS) by bringing E3 ubiquitin ligases and proteins of interest (POIs) together.
  • This catalytic mechanism allows targeting of previously undruggable proteins and overcoming drug resistance.

Purpose of the Study:

  • To critically examine the core principles of PROTAC technology.
  • To provide a functional categorization of PROTACs across various therapeutic areas.
  • To evaluate key technical strategies and current clinical progress in TPD.

Main Methods:

  • Review of existing literature on PROTACs and TPD.
  • Functional categorization based on therapeutic applications (oncology, immunology, neurology).
  • Evaluation of degrader architecture, conditional activation, and delivery platforms.

Main Results:

  • PROTACs offer advantages over traditional inhibitors, including targeting undruggable proteins and overcoming resistance.
  • Challenges include suboptimal pharmacokinetics, the hook effect, and limited E3 ligase usage (CRBN, VHL).
  • Technical innovations focus on improving degrader design, conditional activation, and delivery systems.

Conclusions:

  • PROTACs represent a significant advancement in TPD, with broad therapeutic potential.
  • Addressing current limitations is crucial for advancing PROTACs to next-generation therapeutics.
  • Future directions involve optimizing PROTACs for enhanced efficacy, safety, and broader clinical application.